Top Markets
Coin of the day
Biora Therapeutics, Inc. Biora Therapeutics, Inc.

Biora Therapeutics, Inc.

PROG
Rank in Stocks #27722
Biora Therapeutics, Inc., a biotechnology firm, focuses on the development and... Biora Therapeutics, Inc., a biotechnology firm, focuses on the development and commercialization of molecular diagnostic products within the United States. Its research and development efforts include targeted oral delivery systems for biotherapeutics, such as PGN-600, an oral liquid formulation of tofacitinib for ulcerative colitis, and PGN-001, an orally administered variant of adalimumab also targeting ulcerative colitis. Beyond this, the company is advancing systemic oral biotherapeutic delivery, exemplified by PGN-OB, which combines an adalimumab variant with their Oral Biotherapeutics Delivery System (OBDS) for inflammatory conditions, and PGN-OB2, pairing a GLP-1 receptor agonist with the OBDS for Type 2 diabetes. Biora Therapeutics also creates innovative diagnostic tools, including the Recoverable Sampling System – an ingestible smart capsule engineered to autonomously locate, collect, and preserve samples from the GI tract for analysis – and PIL Dx, another ingestible smart capsule designed to sample, measure, and transmit data wirelessly. A collaboration with Ionis Pharmaceuticals is underway to assess the OBDS platform for delivering antisense oligonucleotides. Founded in 2010 as Ascendant MDX, Inc., the company adopted the name Progenity, Inc. in November 2013, prior to becoming Biora Therapeutics, Inc. Its headquarters are located in San Diego, California.
Share Price
$0.8845
Last synced: 2022-05-06
Market Cap
$31.01M
Change (1 day)
-3.47%
Change (1 year)
0.00%
Country
US
Trade Biora Therapeutics, Inc. (PROG)

Category

Revenue for Biora Therapeutics, Inc. (PROG)
Revenue in Aug 2026 TTM: 0
According to Biora Therapeutics, Inc. latest financial reports the company's current revenue (TTM) is 0. In 2026 the company made a revenue of 0 equal to the revenue in the year 2026 that was 0. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Biora Therapeutics, Inc. from 2026 to 2026
Revenue at the end of each year
Year Revenue Change
Not enough data for the provided dates.
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
$12.62B -
US
$2.23B -
US
$6.02B -
NL
$15.70B -
AU
- -
CH